期刊
EXPERIMENTAL CELL RESEARCH
卷 317, 期 9, 页码 1286-1292出版社
ELSEVIER INC
DOI: 10.1016/j.yexcr.2011.02.017
关键词
Rheumatoid arthritis; Juvenile idiopathic arthritis; IL6R inhibitors; Tocilizumab
A number of clinical trials have been done to investigate the role of interleukin-6 (IL-6) as a potential therapeutic target in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (BA). Most of the data testing this comes from trials of the humanized anti Il-6 receptor antibody tocilizumab. Results from clinical trials worldwide have been promising so far. Additional study will define the ultimate role of tocilizumab and Il6 inhibitors in the treatment paradigms for RA and JIA. (C) 2011 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据